Tenaya Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Tenaya Therapeutics, Inc. (TNYA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 83.00% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-05
- Tenaya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-06-30 was 83.00%.
- Tenaya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 85.00%, a 6.59% decline year-over-year.
- Tenaya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-09-30 was 90.00%.
- Tenaya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-03-31 was 91.00%, a 2.15% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month |
|---|---|
| 2026-06-30 | 83.00% 10-Q · filed 2026-08-05 |
| 2026-03-31 | 85.00% 10-Q · filed 2026-05-06 |
| 2025-09-30 | 90.00% 10-Q · filed 2025-11-10 |
| 2025-03-31 | 91.00% 10-Q · filed 2026-05-06 |
| 2024-06-30 | 92.00% 10-Q · filed 2025-08-06 |
| 2024-03-31 | 93.00% 10-Q · filed 2025-05-07 |
| 2023-09-30 | 94.00% 10-Q · filed 2024-11-06 |
| 2022-03-31 | 97.00% 10-Q · filed 2023-05-10 |
| 2021-06-30 | 103.00% 10-Q · filed 2022-08-10 |
| 2021-03-31 | 183.00% 10-Q · filed 2022-05-11 |
| 2020-09-30 | 183.00% 10-Q · filed 2021-11-10 |
| 2020-06-30 | 182.00% 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |